Acumen® eX3: viable alternative for FMAT analysis
Publication date: 7 August 2009
Author:
Tagged with: TTP LabTech
Royston, UK (4 August 2009) – Today at Drug Discovery and Development (DDT 2009), TTP LabTech has announced the results of two collaborative studies using its renowned Acumen eX3 fluorescence microplate cytometer. Collectively, these data demonstrate that the eX3 is an extremely flexible and robust screening instrument capable of supporting a large number of different assay formats that are key to current drug discovery and development.
The first collaboration involved the analysis of a hybridoma screen using both the FMAT 8100 HTS system (Applied Biosystems) and an Acumen eX3 laser scanning cytometer. Resultant trends for quantification of cell- and bead-based bound antibody were comparable between the two instruments. Data demonstrated that the Acumen is highly suitable for homogeneous binding assays and is a viable alternative to the discontinued FMAT assay detection instruments.
The Acumen eX3’s utility does not stop there and extends beyond simple binding assays into high content screening. A recent collaboration between TTP LabTech and Nerviano Medical Sciences aimed to increase throughput of a complex 4-colour multiplexed cell cycle assay without a deleterious effect on data quality. The Acumen achieved a 4.5 fold increase in throughput and the results proved to be in good concordance with those of the Cellomics ArrayScan. Acumen is the ideal choice for primary screening. It can rapidly identify hits that may be followed up in more detail using the complimentary ArrayScan technology.
Acumen’s strength comes from the powerful combination of high throughput laser scanning data acquisition, plus its simple cytometric approach to data analysis. Both contribute to the generation of extremely fast and robust results. In addition, data file sizes are significantly smaller than those generated by high content imaging technologies. These key features give Acumen eX3 the ability to achieve throughputs analysing over 300,000 wells per day, meaning that it has become an enabling platform for screening departments globally.
For more information visit: www.ttplabtech.com
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content